Daiwa Securities Group Inc. Purchases 200 Shares of Humana Inc. (HUM)
Daiwa Securities Group Inc. boosted its position in shares of Humana Inc. (NYSE:HUM) by 4.7% during the second quarter, Holdings Channel reports. The fund owned 4,450 shares of the insurance provider’s stock after buying an additional 200 shares during the period. Daiwa Securities Group Inc.’s holdings in Humana were worth $1,071,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of HUM. BlackRock Inc. raised its position in shares of Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after buying an additional 11,867,056 shares during the last quarter. FMR LLC raised its position in shares of Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock worth $1,041,184,000 after buying an additional 1,851,197 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after buying an additional 1,231,400 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock worth $159,915,000 after buying an additional 747,557 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Humana by 413.8% in the first quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock worth $151,723,000 after buying an additional 592,772 shares during the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.
Shares of Humana Inc. (NYSE HUM) opened at 251.67 on Friday. Humana Inc. has a 52 week low of $163.50 and a 52 week high of $255.27. The firm has a market capitalization of $36.37 billion, a price-to-earnings ratio of 20.70 and a beta of 0.91. The stock has a 50 day moving average price of $239.25 and a 200-day moving average price of $222.56.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The company had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same quarter in the previous year, the firm earned $2.30 EPS. On average, equities research analysts forecast that Humana Inc. will post $11.55 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/daiwa-securities-group-inc-purchases-200-shares-of-humana-inc-hum/1472512.html.
A number of research analysts recently commented on HUM shares. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $237.00 target price for the company in a research note on Tuesday, April 18th. Citigroup Inc. started coverage on Humana in a research note on Wednesday, June 28th. They issued a “buy” rating and a $275.00 target price for the company. Evercore ISI restated an “outperform” rating and issued a $240.00 target price on shares of Humana in a research note on Tuesday, April 25th. BidaskClub upgraded Humana from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Finally, Jefferies Group LLC restated a “hold” rating and issued a $230.00 target price (up from $221.00) on shares of Humana in a research note on Thursday, May 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $243.65.
In other news, VP Heidi S. Margulis sold 1,500 shares of the business’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the completion of the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the transaction, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by insiders.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.